CBD Oil for Atopic Dermatitis: What Dermatology Says

Atopic dermatitis is one of the most common skin diseases and one of the most troublesome: chronic itching, dryness, cracks, and recurring flare-ups can disrupt sleep for weeks. It is no wonder that many people are looking for something alongside steroid ointment, and manufacturers of hemp cosmetics are eager to respond to this need. The question is how many of these promises are backed by research involving humans. We checked this at the source, and the answer is more restrained than the labels suggest: there are exactly two studies involving patients with atopic dermatitis, and the better-designed one turned out to be unfavorable for cannabidiol itself. This does not mean that the hemp cosmetic is useless, only that the reason it may provide relief may be different from what the packaging claims. Below you will find what exactly was measured, on how many people, for how long, and where knowledge ends and marketing begins.

KEY INFORMATION
• In the only double-blind study on atopic dermatitis (AD), cannabidiol alone did not outperform placebo; the advantage was only provided by the mixture with aspartame (Gao et al., Journal of Cosmetic Dermatology 2022).
• The second study cited by the market was retrospective and involved five patients with AD (Palmieri et al., 2019).
• The skin has its own endocannabinoid system, and its dysregulation is associated with AD, among other conditions (Tóth et al., Molecules 2019).
• The annual prevalence of diagnosed AD in adults ranges from 1.2% in Asia to 17.1% in Europe (Bylund et al., 2020).
• The basis for treating AD remains emollients and medications prescribed by a doctor; hemp cosmetics do not replace them.

How common is AD and who does it really affect?

The numbers circulating on the internet are much less precise than they appear. A systematic review Bylund i wsp. (Acta Dermato-Venereologica, 2020) included 378 studies of moderate or good quality and showed how wide the range is: the annual prevalence of doctor-diagnosed AD in adults ranges from 1.2% in Asia to 17.1% in Europe, and in children in Asia from 0.96% to 22.6%.

This range has practical significance. A single figure like "AD affects 20% of children" is not a universal value, but rather a result from one country and one definition of the disease. The authors of the review point out that the data mainly comes from Europe and the United States, and there is a lack of studies on incidence in adults themselves.

For the reader, this means one thing: AD is common enough for the cosmetics market to notice it, but not uniform enough for one solution to fit all. The manifestation in infants, teenagers, and adults differs in the distribution of lesions and the course of the disease, and thus in what makes sense in care. This is the background against which one must read the promises of manufacturers.

Why are cannabinoids considered in the context of AD?

Because the skin has its own endocannabinoid system, and it is dysregulated in AD. This is not a marketing hypothesis, but a finding from dermatological literature, and it justifies asking questions about cannabidiol.

Review Tóth et al. (Molecules, 2019) collects two decades of work on cannabinoids in the skin. Endocannabinoids, their receptors, and the enzymes responsible for their metabolism are present in the skin, and this signaling plays a role in maintaining epidermal balance, barrier construction, and its reconstruction. The authors mention atopic dermatitis among the diseases where dysregulation of this system plays a role, alongside psoriasis, scleroderma, acne, hair growth disorders, and itching.

The action of cannabidiol itself is best described in relation to the sebaceous gland. Oláh i wsp. (Journal of Clinical Investigation, 2014) They demonstrated in cultures of human sebocytes and in organotypic skin cultures that CBD inhibits lipid production, and this occurs through the TRPV4 ion channel. The anti-inflammatory action took a separate route: through the A2a adenosine receptor and inhibition of the NF-κB pathway. It's worth remembering this, as product descriptions almost always attribute this effect to CB2 receptors, whose role in this capacity is not confirmed.

However, the mechanism is just a premise. The probable biological pathway suggests that it is worth checking, not that it works. Definitive studies on humans with diagnosed disease are what matter, and they are the subject of the next section.

What have clinical studies shown about CBD in relation to AD?

Not much, and what they have shown is less optimistic than the market repeats. The studies involving patients with AD that we found in the literature are two, and only one of them has a control group. In the one with a control group, cannabidiol alone did not prove to be better than placebo.

Gao i wsp. (Journal of Cosmetic Dermatology, 2022) conducted a double-blind study with placebo, in which 57 participants were randomly assigned to three groups: a preparation combining CBD with aspartame, CBD alone, or placebo. After two weeks, the ISGA score, which is the physician's assessment of the severity of lesions, decreased by 1.28 in the combined preparation group, by 0.81 in the CBD alone group, and by 0.71 in the placebo group. Statistical significance was achieved only by the combined preparation. A state of clear or nearly clear skin was achieved by 50% of participants in the combined group compared to 20% in the CBD alone group and 15% in the placebo group.

Drugie badanie to praca Palmieriego i wsp. (La Clinica Terapeutica, 2019), most frequently cited in advertisements. The authors themselves describe it as spontaneous, anecdotal, and retrospective. It involved 20 participants, but only five had AD: the others suffered from psoriasis or had post-inflammatory scars. The CBD ointment was applied twice daily for three months, and improvement was noted in hydration, transepidermal water loss, and skin elasticity. There was no control group or blinding, and the authors do not provide the concentration of cannabidiol in the abstract.

The comparison of these two studies provides an honest and unimpressive picture. The signal is there, it is weak, and in the only study capable of distinguishing the drug's effect from the placebo effect, it favored the combined preparation rather than cannabidiol alone. Any statement saying that "studies confirm the effectiveness of CBD in AD" goes further than the data allows.

Does CBD relieve itching in atopic dermatitis?

None of the two studies described above measured itching as a separate endpoint with a control group. Itching is the most troublesome symptom in AD, as it drives the vicious cycle of scratching and exacerbation, so the question is valid. However, the answer is that there is simply no decisive measurement in these studies.

The work by Gao et al. measured the physician's assessment of lesion severity, not the severity of itching reported by the patient. The study by Palmieri noted improvement in hydration and barrier parameters, but without a control group, it is impossible to determine how much of the perceived relief is attributable to cannabidiol alone, how much to the ointment base, and how much to the passage of time. With a disease that has a wave-like course, the latter possibility is not theoretical.

The base is, by the way, a clue that should not be overlooked. Any greasy ointment applied twice daily acts as an emollient, and emollients are the foundation of care in AD, alleviating dryness and itching regardless of any active ingredient. A CBD cosmetic may help in this way, without the involvement of the ingredient for which you pay extra. This does not invalidate the relief you feel, but it changes what should determine the choice of product: the composition of the base and the absence of irritating substances weigh more here than the declared cannabidiol content. More about external use in eczema is described in the text about hemp ointment for eczema and skin itching.

Does CBD rebuild the skin barrier?

One parameter was indeed measured, but in a study without a control group. It concerns transepidermal water loss, abbreviated as TEWL: the higher it is, the worse the skin retains water, and the easier allergens and microorganisms penetrate it. In atopic dermatitis (AD), it is elevated, and reducing it is a reasonable goal for skincare.

Palmieri et al. noted an improvement in TEWL after three months of using a CBD ointment twice daily. The limitations described above also apply to this result: without a control arm, it is unclear whether the improvement is due to cannabidiol or simply the regular moisturizing of the skin. An emollient without active substances reduces TEWL and is a foundation of AD treatment recognized by dermatology, so an alternative explanation is strong here.

Regardless of who is right, the practical conclusion remains unchanged. Rebuilding the barrier is a process measured in weeks, not days, and requires regular application. Evaluating any product after a few days makes no sense, whether it's a hemp cosmetic or a regular emollient. If after two months of daily use nothing changes, that is a result worth taking seriously instead of increasing the frequency.

How to use CBD cosmetics for atopic dermatitis?

Externally, on the affected areas, as an addition to the skincare routine you are already following. We do not provide milligrams or dosing schemes here: for a skin condition with such a course, it is determined by a doctor who sees your skin, not an article on the internet.

Before you start, do a patch test on a small area. Apply a small amount to the inner side of your forearm and wait a day. Atopic skin reacts to new substances more often than healthy skin, and irritation can be caused by the ointment base, not the active ingredient. Choose products without fragrance compositions and without preservatives known for their irritating potential.

Three things to remember when using:

• An emollient is fundamental, not an addition. It should be used regularly, regardless of whether you are using anything with cannabidiol.
• A hemp cosmetic does not replace a medication prescribed by a doctor and is not a reason to discontinue treatment during a flare-up.
• Assessment takes time. A few weeks of regular use is the minimum to draw any conclusions.

Separately about oral preparations. There is no study examining CBD oil taken orally in patients with AD, so adding it to your skincare routine is a decision without data support. If you are considering it nonetheless, check with your doctor, especially if you are on regular medication.

Can CBD be used in children with AD?

Not without consulting a pediatrician or pediatric dermatologist. AD most often begins in the first years of life, and it is the parents who seek something gentler than a steroid ointment, but there are no data in this group.

Both studies discussed above were conducted in adults. A child's skin is thinner and more permeable, so the absorption of substances applied to a large area of the body can be higher than in adults, and in AD, the barrier is additionally damaged. These are two reasons why the conclusions from studies in adults cannot be directly transferred here, even if that conclusion were strong.

Oral preparations with cannabidiol in children are a separate matter and require a doctor's decision even more. The only well-documented use of CBD in children concerns drug-resistant forms of epilepsy, where a registered medication is used under supervision, for a specific indication. This is not a basis for self-supplementation in skin disease.

Practically, this means a simple order. First, establish emollient care and treatment for flare-ups with your doctor, then possibly ask about a hemp cosmetic as an addition, not the other way around. A parent who postpones a visit because they are trying another over-the-counter product is wasting time during which the condition can worsen.

Does CBD limit Staphylococcus colonization?

In vitro, yes, but this has not been tested in patients with AD. The topic is interesting because atopic skin is excessively colonized by Staphylococcus aureus, and its toxins exacerbate inflammation and itching, closing another vicious circle.

Blaskovich i wsp. (Communications Biology, 2021) They examined the antimicrobial action of cannabidiol and confirmed activity against Gram-positive bacteria, including resistant strains of Staphylococcus aureus. They also noted effectiveness against biofilm, a slight tendency of bacteria to develop resistance, and local action in an animal model, with membrane damage being the main mechanism.

From this result to the statement, "CBD cream will limit Staphylococcus on your skin," is a long way. Concentrations effective in culture may not be achievable in a cosmetic applied to the skin, and no study has examined the effect of such a preparation on the skin microbiome of patients with AD. Treat this as a direction for research, not a reason for purchase.

There is also a reverse trap worth knowing about. Excessive colonization by Staphylococcus in AD largely results from a damaged barrier, so the thing that most effectively limits it is the rebuilding of that barrier and calming inflammation, not antibacterial action in itself. Oozing, crusted skin and increasing pain indicate superinfection, and then treatment prescribed by a doctor is needed, not another cosmetic.

What cannot CBD replace in the treatment of AD?

Nothing from the first line. Daily emollients, topical glucocorticoids during flare-ups, and calcineurin inhibitors in sensitive areas are therapies with evidence incomparably stronger than anything currently known about cannabidiol for this indication.

The interest in hemp cosmetics arises from a real problem: prolonged use of topical steroids has its consequences, and patients and parents are looking for something for the periods between flare-ups. This is a sensible question, and it is precisely here that a hemp preparation may have some role, as a supportive care element, not as a medication.

The boundary, beyond which you need to see a doctor, is clear. Extensive lesions, oozing skin, signs of infection, itching that prevents sleep: in such situations, no cosmetic will suffice, and delaying consultation worsens the prognosis. In severe AD, biological drugs and Janus kinase inhibitors are now used, which have changed the course of the disease for individuals previously without options. Cannabidiol does not stand alongside them, and there is no reason to present it that way. We have written about other uses of cannabidiol on the skin in the text about hemp cosmetics.

Frequently Asked Questions

Does CBD help with atopic dermatitis?

The evidence is weak. In the only double-blind placebo-controlled study involving 57 people, cannabidiol alone reduced the ISGA score by 0.81 compared to 0.71 for placebo, which is not statistically significant; a combination product of CBD with aspartame achieved a greater advantage (Gao et al., 2022). The second cited study was retrospective and involved five patients with atopic dermatitis.

How to use CBD cosmetics for atopic dermatitis?

Externally, on affected areas, as a supplement to care, not as a substitute. Before the first use, do a patch test on your forearm and wait a day, as atopic skin reacts to new substances more often than healthy skin. We do not provide milligrams or a regimen: for skin diseases, this is determined by the doctor who examines it.

Can CBD cosmetics replace steroid ointment?

No. Topical glucocorticoids and calcineurin inhibitors have incomparably stronger evidence, and in severe atopic dermatitis, biological medications and Janus kinase inhibitors are used. The hemp product can be considered as a supportive care element between flare-ups, but never as a substitute for treatment prescribed by a doctor.

Can CBD be used in children with atopic dermatitis?

Not without consulting a pediatrician or pediatric dermatologist. Both clinical studies on atopic dermatitis were conducted in adults. A child's skin is thinner and more permeable, and with atopic dermatitis, the barrier is additionally damaged, so absorption from a large body surface can be higher than in adults.

Does CBD fight staphylococcus on atopic skin?

This has not been studied in humans. Blaskovich et al. (Communications Biology, 2021) demonstrated the action of cannabidiol against Gram-positive bacteria, including resistant strains of Staphylococcus aureus, and against biofilm, mainly by damaging the bacterial membrane. However, no study has examined the effect of CBD cosmetics on the skin microbiome of patients with atopic dermatitis.

Hemp body cosmetics, including creams and balms, can be found in the category cosmetics. Treat them as skincare, not as treatment: in AD, the fundamentals of therapy are determined by a doctor.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use hemp or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Opublikowano: 2026-06-02 · Aktualizacja: 2026-08-15